rxrab Antibody

What is RXRB and why is it an important research target?

RXRB (Retinoid X Receptor beta) is a member of the retinoid X receptor family of nuclear receptors involved in mediating the effects of retinoic acid. It plays a critical role by heterodimerizing with other nuclear hormone receptors, including RAR, the thyroid hormone receptor, and the vitamin D receptor, thereby enhancing DNA binding and transcriptional function on their respective response elements. The gene is located within the major histocompatibility complex (MHC) class II region on chromosome 6, suggesting its potential importance in immune function regulation .

What are the key characteristics of commercially available RXRB antibodies?

Most commercial RXRB antibodies are rabbit polyclonal or monoclonal antibodies that detect the protein at approximately 50-57 kDa, with some antibodies also detecting a 70 kDa form. These antibodies typically show reactivity against human, mouse, and rat RXRB. The immunogens used for antibody production include RXRB fusion proteins and synthetic peptides corresponding to specific regions of the protein, such as residues Q(190) K S D Q G V E G P G A T(202) of mouse RXRB or amino acids 50-100 of human RXRB .

How can I validate the specificity of an RXRB antibody?

Antibody validation should involve multiple approaches:

• Western blot analysis using positive control samples (e.g., NIH/3T3 cells, MCF-7 cells)

• Comparing observed molecular weight (50-57 kDa) with predicted molecular weight

• Testing with knockout/knockdown samples to confirm specificity

• Cross-validation using different antibodies targeting distinct epitopes of RXRB

• Testing in multiple applications (WB, IHC, IF) to confirm consistent results

• Including appropriate negative controls in all experiments

What are the recommended dilutions for RXRB antibodies in different applications?

The following dilution ranges are typically recommended for RXRB antibodies, though optimal concentrations should be determined empirically for each experimental system:

These dilutions represent starting points, and researchers should perform titration experiments to determine optimal antibody concentrations for their specific experimental conditions .

What is the best method for detecting RXRB in nuclear fractions?

For nuclear protein detection of RXRB:

• Perform careful nuclear and cytoplasmic fractionation using specialized buffers

• Add protease and phosphatase inhibitors to prevent protein degradation

• Use 4-12% gradient gels for optimal separation

• Include positive controls (such as MCF-7 cells) known to express RXRB

• Consider using chromatin immunoprecipitation (ChIP) for studying DNA-bound RXRB

• Include loading controls specific for nuclear fractions (e.g., Lamin B1, HDAC1)

• Use gel shift assays to detect functional activity, particularly when studying receptor binding to response elements

How can I optimize antigen retrieval for RXRB immunohistochemistry?

For optimal antigen retrieval in RXRB immunohistochemistry:

• Primary recommendation: Use TE buffer at pH 9.0 for heat-induced epitope retrieval

• Alternative method: Citrate buffer at pH 6.0 may be used if TE buffer produces high background

• Retrieval time should be optimized (typically 15-20 minutes)

• Allow slides to cool gradually to room temperature following retrieval

• Include positive control tissues (e.g., human kidney, mouse heart)

• Block thoroughly with 3-5% BSA or serum matched to secondary antibody species

• Dilute antibody in the range of 1:20-1:200 based on tissue type and fixation method

Why might I observe multiple bands when using RXRB antibodies in Western blot?

Multiple bands in RXRB Western blots may occur due to:

• Post-translational modifications - RXRB undergoes phosphorylation and SUMOylation

• Alternative splicing - Different isoforms ranging from 50-57 kDa

• Protein degradation - Incomplete protease inhibition during sample preparation

• Cross-reactivity with related proteins - RXRB shares homology with RXRA and RXRG

• Non-specific binding - Particularly in crude lysates or with insufficient blocking

The 70 kDa band sometimes observed with RXRB antibodies may represent a post-translationally modified form or a complex with another protein. Always include positive controls and compare observed patterns with literature reports .

How can I reduce background in immunofluorescence experiments with RXRB antibodies?

To reduce background in RXRB immunofluorescence:

• Optimize fixation - Test both paraformaldehyde (4%) and methanol fixation

• Increase blocking stringency - Use 5-10% normal serum with 0.3% Triton X-100

• Extend blocking time to 1-2 hours at room temperature

• Dilute primary antibody appropriately (start with 1:10-1:100 range)

• Include 0.1-0.3% BSA in antibody dilution buffer

• Extend washing steps (5x 5 minutes) with PBS containing 0.1% Tween-20

• Consider using specialized mounting media containing anti-fade reagents

• Compare different secondary antibodies to find optimal signal-to-noise ratio

What are the main factors affecting reproducibility when using RXRB antibodies?

Key factors affecting reproducibility include:

• Antibody lot-to-lot variation - Document lot numbers and validate each new lot

• Sample preparation inconsistencies - Standardize lysis buffers and procedures

• Storage conditions - Maintain antibodies at -20°C with glycerol and avoid freeze-thaw cycles

• Cell culture variations - Control cell density, passage number, and treatment conditions

• Equipment variations - Calibrate imaging systems and standardize exposure settings

• Quantification methods - Use consistent analysis approaches for densitometry

• Protein loading amounts - Validate loading controls and protein quantification methods

• Buffer composition changes - Document and standardize all buffer components

How can RXRB antibodies be used in ChIP assays to study transcriptional regulation?

For ChIP applications with RXRB antibodies:

• Crosslink cells with 1% formaldehyde for 10 minutes at room temperature

• Sonicate chromatin to 200-500 bp fragments

• Use 2-5 μg of ChIP-certified anti-RXRB antibody per immunoprecipitation

• Include appropriate controls (IgG negative control, positive control for a known RXRB target)

• Design primers for putative RXRE (RXR response elements) in genes of interest

• Consider ChIP-seq for genome-wide analysis of RXRB binding sites

• Validate findings with reporter assays or functional studies

• Analyze co-occupancy with heterodimeric partners (RAR, VDR, TR) through sequential ChIP

What approaches can be used to study RXRB heterodimerization with partner nuclear receptors?

To study RXRB heterodimerization:

• Co-immunoprecipitation using RXRB antibodies followed by immunoblotting for partner receptors

• Gel shift assays with purified proteins and labeled response elements - PA1-815 antibody has been validated for supershifting VDR/RXR beta/VDRE complexes

• Proximity ligation assays to visualize protein interactions in situ

• FRET or BRET assays using tagged proteins to measure direct interactions

• Mammalian two-hybrid assays to map interaction domains

• Sequential ChIP (Re-ChIP) to identify genomic regions bound by both RXRB and partner receptors

• Mass spectrometry analysis of RXRB immunoprecipitates to identify novel interaction partners

How can I develop phospho-specific antibodies for studying RXRB post-translational modifications?

Drawing from approaches used for other phospho-specific antibodies:

• Identify specific phosphorylation sites through phospho-proteomic analysis or literature

• Generate peptides containing the phosphorylated residue of interest

• Produce both phosphorylated and non-phosphorylated peptides for screening

• Immunize rabbits and select antibodies with high phospho-selectivity

• Perform extensive validation using:

  • Phosphatase-treated samples as negative controls

  • Kinase activation/inhibition to modulate phosphorylation

  • Mutagenesis of phosphorylation sites

  • Western blot, IP, and IHC applications to confirm specificity

• Consider developing monoclonal antibodies for superior reproducibility and specificity

How should I quantify and normalize RXRB protein levels in Western blot experiments?

For accurate RXRB quantification:

• Use appropriate loading controls (β-actin, GAPDH for whole cell; Lamin B1 for nuclear fractions)

• Perform linear range determination to ensure signals are within quantifiable range

• Use technical replicates (minimum of 3) for statistical validity

• Apply digital image analysis software with background subtraction

• Report results as relative fold change compared to control samples

• Consider using standardized recombinant protein for absolute quantification

• When comparing across different blots, include a common reference sample

• Validate findings with orthogonal methods (qPCR, functional assays)

What controls are essential when measuring RXRB expression in patient samples?

Essential controls for clinical samples include:

• Technical controls:

  • Positive control tissues (e.g., human kidney, colon cancer tissue)

  • Negative control tissues (tissues with minimal RXRB expression)

  • Isotype control antibodies to assess non-specific binding

  • No primary antibody controls for background assessment

• Biological controls:

  • Normal adjacent tissue from the same patient

  • Age and gender-matched normal tissues

  • Tissue microarrays for parallel processing of multiple samples

  • Known clinical samples with validated RXRB expression patterns

• Analytical controls:

  • Standardized scoring systems for immunohistochemistry (H-score, Allred, etc.)

  • Blinded assessment by multiple observers

  • Digital pathology quantification to reduce subjective interpretation

How can I accurately determine if experimental treatments affect RXRB function rather than just expression?

To assess functional changes distinct from expression changes:

• Compare protein levels (Western blot) with mRNA levels (qPCR) to distinguish transcriptional from post-transcriptional effects

• Use reporter assays with RXRE-driven luciferase to measure transcriptional activity

• Perform ChIP assays to assess DNA binding at target gene promoters

• Analyze nuclear translocation through subcellular fractionation or imaging

• Study heterodimerization patterns through co-immunoprecipitation

• Evaluate post-translational modifications (phosphorylation, SUMOylation) that affect function

• Assess recruitment of co-activators/co-repressors through proteomics approaches

• Correlate findings with downstream target gene expression

How can RXRB antibodies be adapted for single-cell analysis techniques?

For single-cell applications with RXRB antibodies:

• Optimize antibody conjugation protocols for direct fluorophore labeling

• Validate specificity in fixed and permeabilized cells using flow cytometry

• Determine optimal concentrations that minimize background in CyTOF applications

• Test compatibility with multiplexing approaches using other nuclear receptor antibodies

• Develop protocols for intracellular staining compatible with cell sorting

• Consider proximity extension assays for ultrasensitive protein detection

• Validate antibodies for single-cell Western blot technologies

• Develop imaging mass cytometry protocols for spatial protein analysis

What are the considerations for studying RXRB in non-traditional model organisms?

When studying RXRB in non-traditional models:

• Perform sequence alignment analysis to predict cross-reactivity

• Test multiple antibodies raised against different epitopes

• Include positive controls from validated species (human, mouse, rat)

• Consider generating custom antibodies against conserved epitopes

• Validate specificity using recombinant proteins or overexpression systems

• Optimize extraction protocols for tissue-specific factors

• Perform careful titration experiments to determine optimal concentrations

• Consider using molecular approaches (CRISPR tagging) if antibodies show poor specificity

How can computational approaches enhance RXRB antibody-based research?

Computational approaches to enhance antibody research:

• Epitope prediction algorithms to identify optimal immunogen selection

• Structural modeling of RXRB to understand epitope accessibility

• Network analysis to predict functional partners and pathways

• Integration of ChIP-seq with transcriptomic data to identify direct targets

• Machine learning approaches for automated image analysis in IHC/IF

• Molecular dynamics simulations to predict effects of mutations on antibody binding

• Meta-analysis of publicly available RXRB expression data across tissues and disease states

• Systems biology approaches to model RXRB signaling networks